Saffron, as an adjunct therapy, contributes to relieve depression symptoms: An umbrella meta-analysis

• Published in: Pharmacological research 2022-01, Vol.175, p.105963, Article 105963
• Main Authors: Musazadeh, Vali, Zarezadeh, Meysam, Faghfouri, Amir Hossein, Keramati, Majid, Ghoreishi, Zohreh, Farnam, Alireza
• Format: Article
• Language: English
• Subjects: Antidepressive Agents - therapeutic use; Crocus; Crocus sativus L; Depression; Depression - drug therapy; Humans; Phytotherapy; Plant Preparations - therapeutic use; Saffron; Umbrella meta-analysis
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2021.105963

Saffron is a traditional herbal medicine that has been used to treat various ailments such as depressive mood. However, the findings of several meta-analyses regarding anti-depressive properties of saffron (Crocus sativus L.) are controversial. The current umbrella meta-analysis was carried out to determine the magnitude and direction of saffron administration on depression. Relevant studies were searched in international databases including PubMed, Scopus, EMBASE, Web of Science, and Cochrane Central Library up to June 2021. Meta-analysis studies investigating the effects of saffron on depression were considered to include in the study. Random-effects model was used to perform the meta-analysis. Additional analyses including subgroup and sensitivity analyses were carried out. Overall, 7 meta-analyses were included in the study. The results demonstrated that the consumption of saffron resulted in a significant reduction in BDI scores (ES: −3.87; 95% CI: −5.27, −2.46). However, saffron did not change the HAMD scores (ES: −2.10; 95% CI: −5.05, 0.86, p = 0.164) and mixed scores (HAM-D/BDI/DASS) (ES: 0.02; 95% CI: −0.39, 0.43,p = 0.941). Present umbrella meta-analysis demonstrated that saffron intake might contribute to alleviation of depression disorder, however, it cannot be considered as a single therapeutic approach to treat depression. [Display omitted]